This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
INS / Insulin · IHC design guide
Design Immunohistochemistry for INS
Plan chromogenic IHC on paraffin sections using pancreatic endocrine cells as the positive staining benchmark (HPA tissue IHC). This guide covers fixation, localisation and interpretation of a secreted protein (UniProt).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
INS Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Cytoplasmic in pancreatic islets (HPA tissue IHC) | |
| Staining pattern | High cytoplasmic staining in pancreatic endocrine cells (HPA tissue IHC) | |
| Antigen retrieval | Citrate pH 6.0 HIER, 95–98 °C, 20 min (rule: cytoplasmic / membrane antigen) | |
| Positive control | Pancreas | |
| Negative control | Adipose tissue+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Matched tissue-IHC evidence does not establish the fixation claim. Validate the specimen-specific method before use. (selected-SKU IHC image M00067-1) | |
| Caveat | Secreted insulin: RNA and protein sites may differ (HPA tissue IHC) | |
| Regulation | Beta-cell expression; regulation unknown (UniProt) | |
| Isoform / epitope | 2 isoforms; precursor processing may affect epitope recognition (UniProt) |
Section 1
Recommended INS IHC & IF Protocols
The catalog antibody’s IHC-P protocol is accompanied by published insulin staining methods for gut and human pancreas (PMC3315609; PMC10036285; PMC13310234).
| Sample | Paraffin-embedded mouse pancreas tissue; fixative not specified (datasheet M00067-1) |
| Fixation | Image fixative and duration unreported (datasheet M00067-1); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat-induced epitope retrieval in citrate buffer, pH 6.0, 20 min at 95–98 °C (standard rule: cytoplasmic / membrane antigen) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% normal serum of the secondary host, 30 min, room temperature (standard) |
| Primary antibody | Rabbit monoclonal (clone DEA-9) anti-INS, 1:50 (datasheet M00067-1) |
| Primary incubation | Overnight at 4 °C (standard) |
| Detection | HRP-polymer secondary, DAB chromogen 5–10 min (standard) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | INS-positive staining in pancreatic endocrine cells of pancreas (HPA tissue IHC: High). HPA tissue profile: Highly selective cytoplasmic expression in pancreatic islets. No signal in the no-primary control. |
💡Decision noteStart with citrate pH 6.0 HIER at 95–98 °C for 20 min (page antigen-retrieval rule); the cited excerpts give no retrieval conditions.
Section 2
What Is the Expected INS Staining Pattern?
INS is a secreted protein without a transmembrane segment (UniProt P01308 topology). In tissue IHC, expect strong cytoplasmic staining in pancreatic islets, particularly beta cells (HPA: highly selective cytoplasmic islet expression; UniProt P01308: beta-cell expression). HPA rates the tissue pattern Enhanced because antibody staining agrees closely with RNA expression; for a secreted protein, RNA and protein locations can differ (HPA: reliability description).
| Strong cytoplasmic signal in pancreatic islet cells, with little staining in surrounding tissue. | This matches the reported high staining of pancreatic endocrine cells and highly selective islet pattern (HPA: pancreas tissue IHC). Interpret the positive cells as consistent with INS; morphology alone does not identify every endocrine cell as a beta cell. |
| Predominantly nuclear or crisp cell-surface signal replaces the islet cytoplasmic pattern. | That compartment is discordant with the reported cytoplasmic pattern and secreted, non-transmembrane topology (HPA: tissue IHC; UniProt P01308 topology). Check staining controls and section morphology before assigning it to INS. |
| Strong staining occurs mainly outside pancreatic islets or in an HPA negative tissue. | This conflicts with HPA's highly selective islet pattern; adipocytes in adipose tissue, for example, are reported as not detected (HPA: tissue IHC). Investigate nonspecific binding or endogenous detection activity before calling it INS. |
| A weak, uniform haze covers endocrine and surrounding cells. | A uniform haze cannot resolve the selective cytoplasmic islet pattern reported by HPA (HPA: tissue IHC). In chromogenic IHC, review antibody dilution, blocking, washes and detection background before scoring cells as positive. |
| A pancreatic section with recognizable islets shows no convincing islet signal. | That result is discordant with high pancreatic endocrine-cell staining (HPA: pancreas tissue IHC). First verify that the section contains islets, then review antibody validation, retrieval and detection controls; absence of signal alone does not establish absent INS. |
💡Expected INS appearanceCall a slide positive when pancreatic islet cells show high cytoplasmic staining (HPA: pancreas tissue IHC); dominant nuclear, surface or widespread non-islet staining is discordant with the reported pattern (HPA: tissue IHC; UniProt P01308 topology).
| Tissue and cell context | Pancreatic endocrine cells are reported High, and the overall tissue profile is highly selective for islet cytoplasm (HPA: tissue IHC). UniProt places INS expression in beta cells; HPA's broader endocrine-cell label does not establish that every stained endocrine cell is a beta cell (UniProt P01308; HPA: pancreas tissue IHC). |
| Secretion and processing | INS is secreted and has an annotated signal peptide at residues 1–24 and propeptide at 57–87 (UniProt P01308). These annotations do not identify the antibody epitope or predict which processed forms this assay detects. HPA also cautions that protein and RNA tissue locations may differ for secreted proteins (HPA: reliability description). |
| Antibody evidence | Four listed antibodies have Enhanced IHC status (HPA: antibody validation). The tissue profile also has Enhanced reliability from staining and RNA consistency (HPA: reliability description). Use those findings to support the expected pattern, while assessing background and controls in the actual run. |
| Chromogenic detection background | Endogenous enzyme activity and nonspecific detection can produce color unrelated to the primary antibody (general IHC practice). A no-primary control and appropriate enzyme blocking help distinguish that background from the selective islet pattern (HPA: tissue IHC). |
| IF/ICC: what pattern is established? | HPA labels INS secreted but provides no main ICC-IF location or cell-line images, and ICC validation is unlisted for the supplied antibodies (HPA: subcellular and antibody records). Use the cytoplasmic pancreatic-islet IHC pattern only as tissue context; this record does not establish an IF/ICC staining pattern. |
| Situation | Likely cause | Next action |
|---|---|---|
| No signal in a pancreatic islet positive control. | The result conflicts with high staining reported in pancreatic endocrine cells (HPA: pancreas tissue IHC). A failed staining step or an islet-free section are practical possibilities. | Confirm islets on the section, then check antibody identity, dilution, retrieval, detection reagents and control performance (general IHC practice). Do not infer INS absence until the positive control stains. |
| Broad staining obscures the boundary between islets and surrounding tissue. | The distribution conflicts with highly selective islet staining (HPA: tissue IHC). Excess background from primary or detection reagents is a practical possibility. | Compare with a no-primary control; review antibody dilution, blocking and washes (general IHC practice). Score INS only where cellular staining remains distinguishable from background. |
| The strongest signal appears nuclear or along cell borders. | Those locations disagree with HPA's cytoplasmic tissue pattern; INS has no transmembrane segment (HPA: tissue IHC; UniProt P01308 topology). | Inspect counterstain and morphology, compare controls, and reassess reagent specificity before interpreting the signal as INS (general IHC practice). |
| An HPA negative tissue shows convincing chromogen deposition. | For example, HPA reports no detection in adipose-tissue adipocytes (HPA: adipose tissue IHC). Cross-reactivity or endogenous detection activity could account for staining. | Check a no-primary control and enzyme blocking, then compare the cell type and distribution with the reported HPA negative result (general IHC practice; HPA: tissue IHC). |
| Signal varies sharply across one section or collects at its edge. | Uneven reagent coverage or section handling can cause spatial artifacts (general IHC practice); that distribution is not the reported selective islet pattern (HPA: tissue IHC). | Check section integrity and reagent coverage, repeat staining if needed, and interpret only intact regions with readable islet morphology (general IHC practice). |
| Only some pancreatic endocrine cells stain. | HPA reports high staining in pancreatic endocrine cells but does not state that every endocrine cell stains (HPA: pancreas tissue IHC). UniProt specifies beta-cell expression (UniProt P01308). | Judge the cytoplasmic signal within identifiable islets and avoid treating every unstained endocrine cell as a technical failure. Use an appropriate cell-identity marker if exact cell assignment is required (general IHC practice). |
Experiment evidence
IHC & IF images showing INS staining
M00067-1 · IHCImmunohistochemical analysis of paraffin-embedded mouse pancreas, using Insulin Antibody.
M00067-1 · IFImmunofluorescent analysis of BxPC-3 cells, using Insulin Antibody .
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000254647-INS/tissue/cerebral+cortex#imid_14189252
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000254647-INS/tissue/colon#imid_14189178
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000254647-INS/tissue/liver#imid_14189179
HPA · PancreasHuman Protein Atlas IHC, Pancreas. Source: https://www.proteinatlas.org/ENSG00000254647-INS/tissue/pancreas#imid_14189122
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for INS IHC & IF
🧪Run pancreas first: pancreatic endocrine cells should stain for INS (HPA: High in pancreatic endocrine cells; UniProt P01308: expressed by pancreatic beta-cells). Use adipose tissue as a negative tissue (HPA: Not detected in adipocytes); nonendocrine cells on the pancreas slide should provide an internal negative comparison (UniProt P01308: expression in pancreatic beta-cells).
Positive control tissue: Pancreas (Pancreatic endocrine cells, HPA High)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA carries no ICC-IF cell line for INS; derive a cell-line control from the positive tissue's cell type (Pancreatic endocrine cells) and confirm it by RNA or western blot first.
Technical controls: Include a no-primary (secondary-only) control, an irrelevant antibody matched to the primary antibody’s host species and clonality, and INS-knockout tissue as a biological specificity control where available (standard IHC controls). For pancreas, block endogenous peroxidase in chromogenic IHC and assess autofluorescence if using IF (standard IHC/IF practice).
⚠️Feasibility: Paraffin-section IHC in mouse pancreas is shown, but the selected M00067-1 caption does not report the fixative (M00067-1 tissue-IHC caption). A target-specific fixation window, the effect of fixation, and antigen-retrieval dependence are unreported in the supplied evidence; the caption therefore cannot establish fixation (M00067-1 tissue-IHC caption). The supplied evidence does not establish whether frozen sections or IF are easier; pancreatic background from endogenous peroxidase or autofluorescence should be checked with the corresponding controls (standard IHC/IF practice). The selected M00067-1 tissue-IHC caption documents paraffin sections, but does not specify the fixative (selected-SKU IHC image M00067-1).
HPA tissue IHC evidence for INS
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Enhanced — High consistency between antibody staining and RNA expression data. Secreted protein, tissue location of RNA and protein is expected to differ.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Pancreas | Pancreatic endocrine cells | High | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Adrenal gland | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Appendix | Endocrine cells | Not detected | Protein (IHC) | HPA → |
| Bone marrow | Hematopoietic cells | Not detected | Protein (IHC) | HPA → |
| Breast | Adipocytes | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced INS IHC Tips
Troubleshoot chromogenic insulin IHC in paraffin sections by checking retrieval, tissue preservation, cellular pattern, controls, and scoring together.
What should I change if insulin staining is weak after retrieval?
Use citrate pH 6.0 HIER at 95–98 °C for 20 min (page retrieval setting). Confirm that the sections stayed immersed, then cool them consistently before antibody incubation; uneven heating can make islets stain unevenly (general IHC practice). Compare a small retrieval time series while keeping antibody incubation and chromogen development constant, and inspect morphology alongside signal (general IHC practice). If staining remains weak, test a different buffer or pH only as a fallback, with a matched section processed under the page setting (general IHC practice). Judge improvement by selective cytoplasmic staining in pancreatic islets, not by stronger staining everywhere (HPA: highly selective cytoplasmic islet expression).
Could fixation explain weak or patchy insulin staining?
Target-specific fixation sensitivity is unknown from the supplied evidence; the selected M00067-1 caption identifies paraffin-embedded mouse pancreas but does not state its fixative (selected IHC caption: M00067-1). Record the actual fixative and fixation interval for each specimen before attributing weak staining to fixation (general IHC practice). Compare sections from tissue processed under documented conditions with the same retrieval, antibody incubation, and detection steps (general IHC practice). Check whether islet morphology and counterstaining are preserved, because damaged or unevenly processed areas are poor grounds for judging antigen loss (general IHC practice). Do not infer fixation tolerance from the HPA staining pattern or insulin’s sequence annotations (HPA: islet expression; UniProt P01308: protein record).
Where should a convincing insulin IHC signal appear?
Expect predominantly cytoplasmic staining in pancreatic islets (HPA: highly selective cytoplasmic expression in pancreatic islets). Insulin is produced by pancreatic beta-cells and annotated as secreted, with no transmembrane segment (UniProt P01308: tissue specificity, localisation, topology). Inspect cellular boundaries and the counterstain at high magnification before calling a diffuse brown deposit intracellular (general IHC practice). A crisp nuclear-only or continuous cell-surface pattern conflicts with the supplied localisation evidence and warrants review of background, section damage, and antibody specificity (HPA: cytoplasmic islet expression; UniProt P01308: secreted, no transmembrane segment). Use neighbouring non-islet tissue as an internal pattern check, while interpreting the staining in the context of preserved morphology (general IHC practice).
Can this stain distinguish mature insulin from its precursor or isoforms?
Do not assign a stained cell to mature insulin, precursor, or a particular isoform without an epitope map for the antibody (general IHC interpretation practice). The record lists 2 isoforms, a signal peptide at residues 1–24, and a propeptide at residues 57–87 (UniProt P01308: isoforms and processing). Mature insulin contains A and B chains linked by disulfide bonds, so processing changes which sequence regions remain in the final hormone (UniProt P01308: subunit and processing). Ask whether the immunogen and validated epitope span a retained or removed region before interpreting differences in staining intensity (general antibody validation practice). Report the result as insulin immunoreactivity when that distinction cannot be established (general IHC reporting practice).
How should I adapt insulin staining for a multiplex IF experiment?
Treat IF/ICC as a separate assay requiring its own antibody validation and controls; the selected M00067-1 image documents paraffin-section IHC only (selected IHC caption: M00067-1). Multiplex insulin with an independently validated pancreatic beta-cell marker, and check each channel alone for bleed-through before interpreting overlap (UniProt P01308: beta-cell expression; general IF practice). Choose a fluorophore channel with low background in the specimen and assess tissue autofluorescence using an unstained control (general IF practice). Insulin has no transmembrane segment and is expected within producing cells before secretion, so use controlled permeabilisation when the antibody must reach an intracellular epitope (UniProt P01308: topology and secretion; general IF practice). Avoid assigning an IF fixation condition from the IHC caption, which does not report a fixative (selected IHC caption: M00067-1).
How can I separate specific islet staining from brown background?
First compare the suspected signal with the expected selective cytoplasmic islet pattern (HPA: highly selective cytoplasmic expression in pancreatic islets). Include a no-primary control and examine whether brown colour persists around tissue folds, cut edges, or poorly preserved areas (general chromogenic IHC practice). If using peroxidase-based detection, check the peroxide block and inspect the no-primary section for residual endogenous activity; these are workflow checks, not insulin-specific findings (general IHC practice). Titrate antibody incubation and chromogen development against a documented positive section without accepting widespread non-islet colour as improved sensitivity (general IHC practice). HPA reports insulin as not detected in several sampled non-pancreatic cell populations, but those observations do not validate every tissue as a negative control (HPA: tissue IHC profile).
How should I score insulin-positive cells across pancreas sections? ⚠ ANSWER MARKED FOR VERIFICATION
Define islet regions on the counterstained section before scoring and apply the same inclusion rules to every specimen (general IHC quantification practice). Within those regions, report the percentage of insulin-positive endocrine cells and, if intensity matters, an H-score from 0–300 using consistent intensity thresholds (general IHC quantification practice). Normalise cell counts to the number of evaluable islet cells, or normalise positive area to measured islet area, rather than to the whole section (general IHC quantification practice). Record the number of sections and islets assessed per specimen, and exclude folds or damaged tissue by a preset rule (general IHC quantification practice). This region-based approach follows the reported selective cytoplasmic islet pattern (HPA: tissue IHC profile).
When is an insulin-positive result likely to be artefactual?
A convincing result shows cellular cytoplasmic staining in pancreatic islets with preserved morphology (HPA: highly selective cytoplasmic islet expression). Insulin is secreted by pancreatic beta-cells, so brown colour outside an identifiable cell should not automatically be counted as another insulin-producing cell (UniProt P01308: tissue specificity and secretion; general IHC interpretation practice). Recheck nuclear-only staining, unexpected non-islet cells, edge deposits, and necrotic areas against the counterstain and a no-primary control (HPA: cytoplasmic islet pattern; general IHC practice). For peroxidase detection, persistent colour in that control points toward endogenous enzyme activity or detection background that needs investigation (general chromogenic IHC practice). Interpret weak or disputed staining with the documented processing and retrieval conditions, since the selected caption does not state a fixative (selected IHC caption: M00067-1).
Boster reagents
Best INS / Insulin IHC Antibodies
The catalog antibody M00067-1 has IHC data from paraffin-embedded mouse pancreas and IF data from BxPC-3 cells (catalog image captions); Human, Mouse and Rat reactivity is listed (catalog reactivity).
Real IHC data
Anti-Insulin Rabbit Monoclonal Antibody
Cat # M00067-1
M00067-1 will render with an IHC image of paraffin-embedded mouse pancreas (IHC image caption). Its IF image shows BxPC-3 cells; the catalog lists IHC, IF and ICC applications and Human, Mouse and Rat reactivity (IF image caption; catalog applications and reactivity).
Which to pick: Choose M00067-1 for tissue IHC when working with paraffin sections, as shown in its mouse pancreas image; the fixative is unreported (IHC image caption). Choose M00067-1 for IF/ICC because IF and ICC are listed applications and its IF image shows BxPC-3 cells (catalog applications; IF image caption). For work across Human, Mouse and Rat, M00067-1 is the listed rabbit monoclonal option, clone DEA-9; the images document mouse tissue IHC and BxPC-3 cell IF (catalog reactivity, host and clone; IHC and IF image captions).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry P01308 (INS_HUMAN, Insulin).
- Human Protein Atlas. INS tissue IHC expression (reliability: Enhanced).
- Human Protein Atlas. INS subcellular location (ICC-IF): Secreted.
- Human Protein Atlas. INS antibody validation summary (4 antibodies).
- Characterisation of Ppy-lineage cells clarifies the functional heterogeneity of pancreatic beta cells in mice. Diabetologia 2021 — PMC8563568.
- Generation of functional insulin-producing cells in the gut by Foxo1 ablation. Nature genetics 2012 — PMC3315609.
- Presence of immunogenic alternatively spliced insulin gene product in human pancreatic delta cells. Diabetologia 2023 — PMC10036285.
- Deep learning-powered quantification of endocrine cells and CD3(+) T cells in the natural history of type 1 diabetes. Diabetologia 2026 — PMC13310234.
- PubMed PMID:6243748 — UniProt-cited evidence.
- PubMed PMID:6248962 — UniProt-cited evidence.
- PubMed PMID:503234 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for INS (Insulin). Expected localisation Cytoplasmic in pancreatic islets (HPA tissue IHC). Antigen retrieval: Citrate pH 6.0 HIER, 95–98 °C, 20 min (rule: cytoplasmic / membrane antigen). Validated IHC antibody: M00067-1 at 1:50 (the product's own IHC validation image is shown). Controls (HPA): positive Pancreas (Pancreatic endocrine cells); negative Adipose tissue. IHC workflow; specimen preparation unspecified. Protocol steps: 1. Sample: Paraffin-embedded mouse pancreas tissue; fixative not specified (datasheet M00067-1); 2. Fixation: Image fixative and duration unreported (datasheet M00067-1); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat-induced epitope retrieval in citrate buffer, pH 6.0 , 20 min at 95–98 °C…; 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% normal serum of the secondary host, 30 min , room temperature (standard); 8. Primary antibody: Rabbit monoclonal (clone DEA-9) anti-INS, 1:50 (datasheet M00067-1); 9. Primary incubation: Overnight at 4 °C (standard). Watch for: Fixation: Matched tissue-IHC evidence does not establish the fixation claim. Validate the specimen-specific method before use. (selected-SKU IHC image M00067-1); Caveat: Secreted insulin: RNA and protein sites may differ (HPA tissue IHC); Isoform / epitope: 2 isoforms; precursor processing may affect epitope recognition (UniProt); Regulation: Beta-cell expression; regulation unknown (UniProt). Evidence: UniProt P01308, HPA tissue IHC · Enhanced, HPA ICC-IF · Secreted, Datasheet M00067-1, PMC3315609, PMC10036285. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/INS/immunohistochemistry-ihc-guide.